特雷姆2
竞争行为
老年精神病学
疾病
神经学
医学
抗体
精神药理学
神经科学
精神科
免疫学
受体
心理学
内科学
侵略
髓系细胞
作者
Hua Long,Adam Simmons,Arthur J. Mayorga,Brady Burgess,Tuan D. Nguyen,Balasubrahmanyam Budda,Anna Rychkova,Hervé Rhinn,Ilaria Tassi,Michael E. Ward,Felix L. Yeh,Tina Schwabe,Robert Paul,Sara Kenkare-Mitra,Arnon Rosenthal
标识
DOI:10.1186/s13195-024-01599-1
摘要
Variants of the gene triggering receptor expressed on myeloid cells-2 (TREM2) increase the risk of Alzheimer's disease (AD) and other neurodegenerative disorders. Signaling by TREM2, an innate immune receptor expressed by microglia, is thought to enhance phagocytosis of amyloid beta (Aβ) and other damaged proteins, promote microglial proliferation, migration, and survival, and regulate inflammatory signaling. Thus, TREM2 activation has potential to alter the progression of AD. AL002 is an investigational, engineered, humanized monoclonal immunoglobulin G1 (IgG1) antibody designed to target TREM2. In AD mouse models, an AL002 murine variant has been previously shown to induce microglial proliferation and reduce filamentous Aβ plaques and neurite dystrophy.
科研通智能强力驱动
Strongly Powered by AbleSci AI